early cannulation a new model in delivering hemodialysis

29
ASVS Istanbul 2013 Early cannulation, a new model in delivering hemodialysis Jürgen Falkensammer Department of Vascular and Endovascular Surgery Wilhelminenspital Wien

Upload: uvcd

Post on 16-Jul-2015

149 views

Category:

Education


2 download

TRANSCRIPT

ASVSIstanbul 2013

Early cannulation, a new model in delivering hemodialysis

Jürgen Falkensammer

Department of Vascular and Endovascular Surgery

Wilhelminenspital Wien

Falkensammer ASVS Istanbul 2013

Disclosures

Jürgen Falkensammer, MD

I have the following potential conflicts of interest to report:

Honorarium for the presentation

Epidemiology of RRT

Falkensammer ASVS Istanbul 2013

USRDS 2013

Epidemiology of RRT

Falkensammer ASVS Istanbul 2013

USRDS 2013

Access Types

Falkensammer ASVS Istanbul 2013

incident prevalent

DOPPS, Kidney Int. 2002

HD catheters

Falkensammer ASVS Istanbul 2013

• High morbidity caused by

− Thrombosis

− Infection

K/DOQI 2006

Patient Survival

Falkensammer ASVS Istanbul 2013

Dhingra et al, Kidney Int. 2001

diabetic Non - diabetic

Adjusted for age, race, gender, BMI, history of smoking, PVD, CAD, CHF, neoplasm, ability to ambulate and education level

Relative risk of death compared to AVF

Falkensammer ASVS Istanbul 2013

Dhingra et al, Kidney Int. 2001

Adjusted for age, race, gender, BMI, history of smoking, PVD, CAD, CHF, neoplasm, ability to ambulate and education level

HD catheters

Falkensammer ASVS Istanbul 2013

• High morbidity caused by

− Thrombosis

− Infection

• Risk for permanent central venous stenosis or occlusion

• Discomfort and cosmetic disadvantage of an external appliance

• Shorter expected use-life than other access types• Overall lower BFRs, requiring longer dialysis times

K/DOQI 2006

K/DOQI Guidelines

Falkensammer ASVS Istanbul 2013

• Short-term catheters should be used for acute dialysis and for a limited duration in hospitalized patients

Short-term Catheters should not be used in patients with foreseeable chronic HD dependency

K/DOQI 2006

K/DOQI Guidelines

Falkensammer ASVS Istanbul 2013

• Avoid if possible: Long-term catheters

Alternative to long-term catheters?

K/DOQI 2006

K/DOQI Guidelines

Falkensammer ASVS Istanbul 2013

Order of preference for HD access:• radial-cephalic AVF• brachial-cephalic AVF• brachial-basilic transposed AVF +/-• forearm AVG• upper arm AVG• alternative sites

Graft Survival

Falkensammer ASVS Istanbul 2013

DOPPS, Kidney Int. 2002

K/DOQI Guidelines

Falkensammer ASVS Istanbul 2013

Fistula First Strategy

If a primary AVF can not be established, a synthetic AV graft is the next preferred type of vascular access.

Requirements for AV Grafts

Falkensammer ASVS Istanbul 2013

• Easy to implant• Good incorporation• Do not clot• Infection resistant• Easy to cannulate• Does not bleed after cannulation

• Does not form pseudoaneurysms

Requirements for early-cannulation Grafts

Falkensammer ASVS Istanbul 2013

• Does not weep• Is self-sealing• < 24 hours cannulation

Early-access Grafts

Falkensammer ASVS Istanbul 2013

Vectra® Vascular Access Graft

AVflo™ Vascular Access Graft

Gore® Acuseal Vascular Graft

Flixene™ Atrium

Rapidax TM

Polyuretane vs. PTFE

Early-access Grafts

Falkensammer ASVS Istanbul 2013

Multilayered:

Outer layer for tissue integration

Intermediate layer for sealing

Inner layer for blood contact

Special features

Design

Antithrombotic properties

Infection - resistance

Vectra® by Bard

Falkensammer ASVS Istanbul 2013

Polyurethane

Microporous Outer Layer

Monofilament Reinforcement

Self-Sealing Middle Layer

Microporous Inner Layer

AVflo™by Nicast

Falkensammer ASVS Istanbul 2013

Polyurethane

Outer Layer – tissue integration

Middle Layer – self-sealing

Barrier Layer – prevents weeping

Middle Layer – self-sealing

Inner Layer – minimizes platelet adhesion

Gore® Acuseal

Falkensammer ASVS Istanbul 2013

PTFE

PTFE

Silicone

CARMEDA® BioActive Surface (Heparin)

Flixene™ by Atrium

Falkensammer ASVS Istanbul 2013

PTFE

Tissue Surface

HydrostaticProtectionMembrane

Flow surface

Flixene™ - Special Features

Falkensammer ASVS Istanbul 2013

Resistance

Tapered design

Graduated wall thickness

Flixene™ by Atrium

Falkensammer ASVS Istanbul 2013

Low – profile tunneling system

Flixene™ IFG

Falkensammer ASVS Istanbul 2013

AVF vs. PTFE graft

Falkensammer ASVS Istanbul 2013

Patency of autogenous and PTFE upper extermity AV hemodialysis access: A systematic review(Huber et al, JVS 2003)

• Medline-based systematic literature review and meta-analysis of patency data in life table or KM

• 1966-2001: 211 full text articles identified • 34 studies fulfilled the criteria

Huber et al, JVS 2003

18 – Months Patency Rates

Falkensammer ASVS Istanbul 2013

6 months 18 months

Primary patency

AVF 72% 51%

AVG 58% 33%

Secondary patency

AVF 86% 77%

AVG 76% 55%

Huber et al, JVS 2003

6 – Months Patency Rates

Falkensammer ASVS Istanbul 2013

AVF PTFE Flixene Vectra AVflo

Author Huber et al, JVS 2003 Schild AF et al, J Vasc

Access 2011

Kakkos et al. J Vasc Surg

2008

Wijeyaratne et al, J Vasc Access 2011

N = 1849 1245 33 76 35

Primary patency 72% 58% 49% 75% 73%

Secondary patency 86% 76% 80% 85% 82%

Primary assisted patency!

Indications for early – cannulation AV grafts

Falkensammer ASVS Istanbul 2013

• early access• to avoid a HD catheter• as a revision graft / for interposition: no

‚catheter – bridging‘ needed• possibly whenever no native vessels are

available for fistula creation

>> indication for a ‚conventional‘ access graft?